Prothena Corporation plc

168 articles with Prothena Corporation plc

• Prothena to Present at the 2020 Cantor Virtual Global Healthcare Conference on September 15

  9/8/2020

  Prothena Corporation plc, a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced that members of its senior management team will present and participate in the 2020 Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 4:00 PM ET.

• Prothena Announces Updated Timing of Presentation for Phase 2 PASADENA Study Results at International Congress of Parkinson’s Disease and Movement Disorders

  9/3/2020

  Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced updated timing for the presentation of results from Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease. As previously announced, results from Part 1 of the Phase 2 PASADENA study

• Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2020

  9/2/2020

  Prothena Corporation plc announced that in connection with hiring two new employees, the compensation committee of the Company’s board of directors granted the individuals hired by the Company, in the aggregate, options to purchase 60,000 ordinary shares of the Company.

• Prothena Reports Second Quarter 2020 Financial Results and Provides R&D Update

  8/6/2020

  Net cash used in operating and investing activities was $18.7 million in the second quarter and $41.9 million for the first six months of 2020; quarter-end cash and restricted cash position of $336.6 million provides funding to advance a broad pipeline

• Prothena Announces Phase 2 PASADENA Study Results to be Presented at International Congress of Parkinson’s Disease and Movement Disorders

  8/5/2020

  Prothena Corporation plc announced that results from Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease was selected as an oral Top Abstract presentation at the upcoming virtual International Congress of Parkinson’s Disease and Movement Disorders Society.

• Prothena to Report Second Quarter 2020 Financial Results on August 6

  7/30/2020

  Prothena Corporation plc announced that it will report its second quarter and first six months of 2020 financial results on Thursday, August 6, after the close of the U.S. financial markets.

• Prothena to Present at the Jefferies Virtual Healthcare Conference on June 3

  5/27/2020

  Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced that members of its senior management team will present and participate in the Jefferies Virtual Healthcare Conference on Wednesday June 3 at 3:30 PM ET.

• Prothena Reports First Quarter 2020 Financial Results and Provides R&D Update and Updated Financial Guidance

  5/6/2020

  Prothena Corporation plc, a clinical-stage neuroscience company with expertise in protein misfolding, reported financial results for the first quarter of 2020.

• Prothena to Report First Quarter 2020 Financial Results on May 6

  4/29/2020

  Prothena Corporation plc, a clinical-stage neuroscience company with expertise in protein misfolding, announced that it will report its first quarter of 2020 financial results on Wednesday, May 6, 2020, after the close of the U.S. financial markets..

• Prothena Provides Additional Information Regarding Upcoming Annual General Meeting of Shareholders in Response to COVID-19

  4/24/2020

  Prothena Corporation plc (NASDAQ:PRTA) today announced a change in the location of its annual general meeting of shareholder scheduled to be held on Tuesday, May 19, 2020

• Update on Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease

  4/22/2020

  Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced that today Roche provided an update on Part 1 of the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease

• Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 03, 2020

  4/3/2020

  Prothena Corporation plc announced that in connection with hiring an executive on March 30, 2020, the compensation committee of the Company’s board of directors granted the individual hired by Prothena an option to purchase 120,000 shares of the Company’s common stock.

• Baseline Data from Phase 2 PASADENA Study of Prasinezumab (PRX002/RG7935) in Parkinson’s Disease to be Presented at AAT-AD/PD

  3/31/2020

  Prothena Corporation plc announced that baseline data from the Phase 2 PASADENA study of prasinezumab in patients with early Parkinson’s disease will be presented by Roche in an oral presentation at the Advances in Alzheimer’s and Parkinson’s Therapies AAT-AD/PD Focus Meeting, to be held virtually on April 2-5, 2020.

• Prothena Announces Appointment of Brandon Smith as Chief Business Officer

  3/3/2020

  Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today announced the appointment of Brandon Smith as Chief Business Officer

• Prothena Reports Fourth Quarter and Full Year 2019 Financial Results, and Provides Financial Guidance and R&D Update

  2/12/2020

  Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, today reported financial results for the fourth quarter and full year 2019.

• Prothena to Report Fourth Quarter and Full Year 2019 Financial Results and Host Webcast Conference Call on February 12

  2/5/2020

  Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company with expertise in protein misfolding, announced today that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 12, 2020 after the close of the U.S. financial markets.

• Prothena Announces Appointment of Oleg Nodelman to its Board of Directors

  12/5/2019

  Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today the appointment of Oleg Nodelman to its Board of Directors.

• Prothena Reports Third Quarter 2019 Financial Results and Provides R&D Update

  11/5/2019

  Prothena Corporation plc, a clinical-stage neuroscience company, reported financial results for the third quarter and first nine months of 2019.

• Prothena to Report Third Quarter 2019 Financial Results on November 5

  10/29/2019

  Prothena Corporation plc (Nasdaq:PRTA), a clinical-stage neuroscience company, will announce financial results for the third quarter and first nine months of 2019 on November 5, 2019 after the close of the U.S. financial markets.

• Investor Alert: Kaplan Fox Announces Investigation Of Prothena Corporation plc

  7/24/2018

  Kaplan Fox & Kilsheimer LLP is investigating claims on behalf of investors of Prothena Corporation plc